POTENSI ANTIOKSIDATIF MAGNESIUM GLYCINATE DALAM MEMPERBAIKI PROFIL LIPID DAN HOMEOSTATIS GLUKOSA PADA KONDISI OBESITAS
DOI:
https://doi.org/10.59003/nhj.v6i2.2322Keywords:
obesity, magnesium glycinate, blood glucose, total cholesterol, high-fat diet, fructosaAbstract
Obesity is a chronic metabolic disease characterized by excessive fat accumulation resulting from a long-term imbalance between energy intake and expenditure. This condition is closely associated with insulin resistance, chronic inflammation, dyslipidemia, elevated blood glucose, and increased total cholesterol. Magnesium, particularly magnesium glycinate with its high bioavailability and good gastrointestinal tolerability, has attracted considerable attention as a supportive nutritional therapy. This literature review aimed to analyze the effectiveness of magnesium glycinate supplementation on blood glucose and total cholesterol levels in obesity induced by a high-fat and high-fructose diet. This review was conducted by searching scientific articles from PubMed, Scopus, ScienceDirect, SpringerLink, and Google Scholar. Eligible studies were published between 2018 and 2025 and discussed obesity, high-fat high-fructose diet, magnesium glycinate, glucose metabolism, lipid metabolism, and experimental animal studies. Evidence indicates that magnesium glycinate improves insulin sensitivity by activating insulin receptors and GLUT-4 transporters, suppresses chronic inflammation through inhibition of the NF-κB pathway, and reduces oxidative stress. Furthermore, magnesium glycinate improves lipid metabolism by reducing cholesterol synthesis and increasing fatty acid oxidation, thereby contributing to reductions in blood glucose and total cholesterol levels in obesity models. Magnesium glycinate has considerable potential as a supportive therapy for obesity through improvement of glucose and lipid metabolism. Its high bioavailability makes it more effective than several other magnesium formulations in improving hyperglycemia and dyslipidemia.
Downloads
References
Organization WH. Obesity and overweight [Internet]. 2024. Available from: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight
Blüher M. Obesity: Pathophysiology, epidemiology, and management. Nat Rev Endocrinol. 2025.
Patial V. Obesity, chronic inflammation, insulin resistance and metabolic disorders. Front Endocrinol (Lausanne). 2024.
Vekic J, Zeljkovic A, Stefanovic A. Obesity and dyslipidemia: Current evidence and future perspectives. Curr Obes Rep. 2023;12(3):291–303. doi:10.1007/s13679- 023-00535-4
Softic S, Cohen DE, Kahn CR. Role of dietary fructose and hepatic de novo lipogenesis in fatty liver disease. Dig Dis Sci. 2020. doi:10.1007/s10620-020-06184-8
Jensen T, Abdelmalek MF, Sullivan S. Fructose and metabolic disease: Mechanisms and implications. Nat Rev Endocrinol. 2024.
Barbagallo M, Dominguez LJ. Magnesium and metabolic syndrome: Mechanisms and clinical implications. Nutrients. 2023;15(9):2117. doi:10.3390/nu15092117
Gröber U. Magnesium in prevention and therapy. Nutrients. 2024.
Ranade V V, Somberg JC. Bioavailability and pharmacokinetics of magnesium after administration of magnesium salts to humans. Am J Ther. 2022;29(2):e143–51.
Volpe SL. Magnesium and human health. Nutrients. 2023.
Rhee EJ. The influence of obesity and metabolic health on vascular disease. Endocrinology and Metabolism. 2022;37(4) :553 –65 . doi: 10.3803/ EnM.2022.101
Jensen T. Fructose and metabolic dysfunction-associated fatty liver disease. Nat Rev Gastroenterol Hepatol. 2024.
Speakman JR, al. et. Animal models of obesity. Dis Model Mech. 2021;14(6). doi:10.1242/dmm.046995
Fang X. Dietary magnesium intake and metabolic health outcomes: A systematic review and meta-analysis. Front Nutr. 2023.
Rosique-Esteban N, Guasch-Ferré M, Hernández-Alonso P, Salas-Salvadó J. Dietary magnesium and cardiovascular disease: A review with emphasis on diabetes and obesity. Nutrients. 2018;10(2):168. doi:10.3390/nu10020168
Schwalfenberg GK, Genuis SJ. The importance of magnesium in clinical healthcare. Scientifica (Cairo). 2017;2017:4179326. oi:10.1155/2017/4179326
Petersen MC, Shulman GI. Mechanisms of insulin action and insulin resistance. Physiol Rev. 2018. doi:10.1152/physrev.00063.2017
Samuel VT, Shulman GI. Nonalcoholic fatty liver disease, insulin resistance, and ceramides. New England Journal of Medicine. 2019 doi:10.1056/NEJMcibr1901642
Costello RB. Perspective: The case for an evidence-based reference interval for serum magnesium. Advances in Nutrition. 2023.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Yusti Siana

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
NHJ is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Articles in this journal are Open Access articles published under the Creative Commons CC BY-NC-SA License This license permits use, distribution and reproduction in any medium for non-commercial purposes only, provided the original work and source is properly cited.
Any derivative of the original must be distributed under the same license as the original.



















